The global peptic ulcer drugs market is anticipated to grow at a CAGR of around 3.3% during the forecast period 2020 to 2027 and to reach around US$ 39.7 Mn by 2027.
Increasing number of inpatients suffering from chronic diseases, increasing public-private partnership for drug development and government focus on delivering enhanced cares to patients are factors expected to drive the growth of global market. In the United States, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time. H pylori infection accounts for 90% of duodenal ulcers and 70-90% of gastric ulcers. In addition, high investment by major players and focus on development of novel products is expected to support the growth of target market.
Major players approach towards business expansion through strategic acquisition and partnership are factors expected to impact the growth of target market over the forecast period.
In 2020, Processa Pharmaceuticals Inc a global drug manufacturing pharmaceutical company signed a agreement with Yuhan Corp. in order to develop, manufacture and commercialize bowel disorder drug YH12852 worldwide. This agreement is expected to help the company to enhance the expansion of business and increase the revenue share.
In 2020, Cadila Pharmaceuticals Limited a drug manufacturing company launched Esomeprazole tablets for treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc. This product launch is expected to help the company to enhance the business profit and increase the customer base.
In 2019, AbbVie a research-based global biopharmaceutical company received approval for RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor. This is expected to help the company to increase the revenue share.
In 2016, Takeda Pharmaceutical Company received approval for its drug VONOSAP pack 400 and VONOSAP pack 800 to sell in Japan. This approval of product helped the company to enhance the business revenue.
Favorable business policies by the government and emergence of small and mid-size enterprises with innovative solutions are factors expected to boost the growth of target market.
However, factors such as high cost of drug development and stringent government regulations related to product approval are expected to hamper the growth of global peptic ulcer drugs market. In addition, side-effects of drug and changing pricing policies are factors expected to challenge the growth of target market.
Increasing investment by major players and development of medication with low side-effects are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing public-private partnerships for development of innovative products is expected to support the revenue growth of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global market due to rising number of patients suffering from chronic diseases. In addition, player’s presence in the country is increasing due to favorable business policies and large patient pool consuming medications this is expected to support the growth of target market.
Increasing acquisition and partnership activities by players in order to enhance the business is expected to boost the growth of regional market
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Global Peptic Ulcer Drugs Market
2016 – 2027
2020 – 2027
Product, Indication, Distribution Channel and Geography
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Peptic Ulcer Drugs Market Segment Analysis, 2019
The global peptic ulcer drugs market is segmented into product, indication, and distribution channel. The product segment is bifurcated into proton pump inhibitors, potassium-competitive acid blockers (P-CABs), antacids, H2- antagonists, antibiotics, and ulcer protective. Among product the proton pump inhibitors segment is expected to account for significant revenue share in the target market. The distribution channel segment is expected to hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce. Among the distribution channel the e-commerce segment is expected to witness faster growth in the target segment.
The players profiled in the report are GlaxoSmithKline plc., AstraZeneca plc., Takeda Pharmaceutical, Pfizer Inc., Abbvie Inc., Boehringer Ingelheim GmbH, Daewoong Pharmaceutical Co., Ltd., Eisai Co. Ltd., Cadila Healthcare Ltd., and Yuhan Corporation.
Market By Product
Proton Pump Inhibitors
Potassium-Competitive Acid Blockers (P-CABs)
Market By Indication
Gastroesophageal Reflux Disease (GERD)
Market By Distribution Channel
Market By Region
Middle East & Africa
Increasing number of inpatients suffering from chronic diseases, increasing public-private partnership for drug development and government focus on delivering enhanced cares to patients are factors expected to drive the growth of global market.
The global peptic ulcer drugs market in 2027 is expected to be above US$ 39.7 Bn.
In distribution channel the e-commerce segment is growing at faster pace.
The CAGR of the global peptic ulcer drugs market from 2020-2027 is above 3.3%.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are GlaxoSmithKline plc., AstraZeneca plc., Takeda Pharmaceutical, Pfizer Inc., and Abbvie Inc.
The Asia Pacific is expected to account for major revenue share in the global market.